Down-regulation of EZH2 expression in myelodysplastic syndromes-Reference-Cited by-同舟云学术

Down-regulation of EZH2 expression in myelodysplastic syndromes

Published:2016-05 Issue: Volume:44 Page:1-7
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Cabrero Monica,Wei Yue,Yang Hui,Ganan-Gomez Irene,Bohannan Zach,Colla Simona,Marchesini Matteo,Bravo Guillermo Montalban,Takahashi Koichi,Bueso-Ramos Carlos,Garcia-Manero Guillermo

Funder

Fundacion Alfonso Martin-Escudero

University of Texas MD Anderson Cancer Center

Edward P. Evans Foundation

Fundacion Ramon Areces

Cancer Prevention & Research Institute of Texas

generous philanthropic contributions to MD Anderson’s MDS/AML Moon Shot Program

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference25 articles.

1. Myelodysplastic syndromes;Tefferi;N. Engl. J. Med.,2009

2. Clinical effect of point mutations in myelodysplastic syndromes;Bejar;N. Engl. J. Med.,2011

3. The landscape of somatic mutations in Down syndrome-related myeloid disorders;Yoshida;Nat. Genet.,2013

4. The Polycomb group protein EZH2 directly controls DNA methylation;Vire;Nature,2006

5. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome;Yu;Cancer Res.,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients;Leukemia Research;2023-01

2. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes;Modern Pathology;2022-09

3. Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes;Cancer Genomics - Proteomics;2022

4. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia;Cancers;2021-10-08

5. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients;Clinical Epigenetics;2021-04-12